News and Analysis

States must rethink how program integrity is designed and delivered by focusing on four key priorities that enable oversight to scale alongside these programs. The

As clinicians, we learn not to be agreeable, we learn to challenge and sit in discomfort. We ask the hard questions underneath the one being

The MENA evidence gap for selected portfolios is becoming a commercial liability for drugmakers that could have been prevented at the design stage. The post